問卷

TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Pediatrics

更新時間:2023-09-19

張鑾英Chang, Luan-Yin
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 9 個月
  • twffccy@gamil.com

篩選

List

55Cases

2018-01-01 - 2018-12-31

Phase II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2023-10-31 - 2025-06-12

Phase II

Completed
A multicenter, single-arm, open-label study to assess the pharmacokinetics, safety, and tolerability of cefiderocol in hospitalized pediatric patients from birth to < 3 months of age with suspected or confirmed aerobic Gram-negative bacterial infections
  • Condition/Disease

    Gram-Negative Bacterial Infections

  • Test Drug

    Cefiderocol

Participate Sites
2Sites

Not yet recruiting1Sites

Recruiting1Sites

2021-02-01 - 2030-03-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2021-08-30 - 2027-06-17

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting4Sites

2013-08-13 - 2018-01-15

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2016-02-01 - 2016-12-31

Phase I

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2022-10-11 - 2024-12-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2022-12-01 - 2025-08-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2018-06-01 - 2024-12-31

Phase III

Completed
A Phase III, Multiple-center, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of an Adjuvanted Inactivated Enterovirus 71 (EV71) Vaccine in Healthy Infants and Children
  • Condition/Disease

    Enterovirus 71 (EV71)

  • Test Drug

    nactivated EV71 whole viral particles adjuvanted with aluminum (Al(OH)3)

Participate Sites
7Sites

Terminated7Sites

2013-09-01 - 2014-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites